

BIOEQUITYEUROPE.COM

MAY KURSAAL ELKARGUNEA CENTER
12-14 **SAN SEBASTIÁN, SPAIN**

MAY **VIRTUAL**
21-22 **1x1 MEETINGS**

ORGANIZED BY **BIOCENTURY** **EBD**
GROUP

24. BIO€QUITY
EUROPE



RISE ABOVE THE NOISE

This year we will gather in San Sebastián, Spain, Basque Country, to discuss how biotechs can rise above the noise to attract the right investors, partners, and talent.

- Debate how to stand out from the crowd and reach the discussion stage with investors and pharma.
- Meet VCs, CEOs, and BD&L leaders in an intimate setting designed for networking and discussion.
- Discover 100+ emerging biotechs selected for the Presenting, Next Wave and Pre-Seed Company Tracks.
- Dive into European biotech trends with an exclusive conference report from Insights Partner McKinsey & Company.
- Schedule one-to-one meetings; check out the Poster Session; take your conversation outside, onto the beach.

ORGANIZED BY

BIOCENTURY **EBD** GROUP

FOUNDING SPONSOR

Sofinnova
partners

INSIGHTS PARTNER

McKinsey
& Company

REGIONAL HOST COMMITTEE



Gipuzkoako
Foru Aldundia
Diputación Foral
de Gipuzkoa

YSIOS CAPITAL

THE BIO€QUITY EUROPE EXPERIENCE

The industry's premier CEO & investor conference

Where decision-makers gather to network, partner, and debate critical issues facing the biotech industry

Showcasing strategies to succeed in Europe, and for Europe to succeed on the global stage – from capital, to talent, to product and business development, and more

300+ biotech CEOs, 300+ VCs, 150+ CFO/COO/CBOs

2+ DAYS

Of strategic panels and keynotes tailored for C-Suite executives

100+

Presenting companies from Europe, the U.S. and Asia, hand-picked by BioCentury

1x1

Schedule meetings through EBD's partneringONE system

VIP

Peer-to-peer networking

EXCLUSIVE REPORT

McKinsey returns to deliver its 5th conference report on Europe's biotech ecosystem

"BioEquity Europe is a 'must go' for both VCs and CEOs of life science companies in Europe ... it is the event where you can feel the pulse of the industry ..."

Antoine Papiernik
Chairman & Managing Partner
Sofinnova Partners

"BioEquity brings together top stakeholders in the life sciences European VC space. The event stands out by delivering quality thought leadership. For the biotech VC community, this is Europe's flagship event."

Nanna Lüneborg, Ph.D.
General Partner
Forbion

"BioEquity Europe is a great meeting for strategic discussions about access to capital and talent. It's also a key networking event for investors and biopharma executives in Europe."

Paul Peter Tak, M.D., Ph.D.
President & CEO
Candel Therapeutics

"BioEquity is the leading event for the biotech industry in Europe.... It brings all actors together and creates an atmosphere and platform for true networking and business development."

Jorge Santos da Silva, Ph.D.
CEO
MoonLake Immunotherapeutics

"BioEquity is the premier life sciences forum in Europe connecting industry leaders, emerging life science companies, and members of the investment community. The content it delivers is unmatched and makes it a priority event for any decision maker in our industry."

Christoph Broja
Managing Director
EQT Life Sciences



PRESENTING COMPANY CLASS OF 2024

Selected by BioCentury editors, members of the *BioEquity Europe Presenting Company Class of 2024* represent some of the hottest R&D areas, including antibody-drug conjugates, T cell therapies, gene therapies and more.

Abalos Therapeutics GmbH	Ariceum Therapeutics GmbH	Curadh MTR Inc.
Abliva AB	Arthex Biotech S.L.	Curve Therapeutics Ltd.
ACM Biolabs Pte. Ltd.	AstriVax N.V.	Cytoki Pharma ApS
ACM Biosciences AG	Atamyo Therapeutics S.A.S.	DiNAQOR AG
Acousia Therapeutics GmbH	Azafaros B.V.	Disco Pharmaceuticals GmbH
Adcendo ApS	B7 Therapeutics Inc.	Domain Therapeutics S.A.
Addex Therapeutics Ltd.	Bantam Pharmaceutical LLC	EG 427 S.A.S.
Adiposs S.A.	BioCortex	Egle Therapeutics S.A.S.
Aignostics GmbH	Biofidelity Ltd.	EnteroBiotix Ltd.
Alder Therapeutics AB	BiolInvent International AB	Enterome S.A.
Alentis Therapeutics AG	Bioxodes S.A.	Epoqe Pharma ApS
Aleta Biotherapeutics Inc.	bit bio Ltd.	Epsilon Ltd.
AlgoTherapeutix S.A.S.	Bloomsbury Genetic Therapies Ltd.	Ethris GmbH
Alia Therapeutics s.r.l.	Brainomix Ltd.	Evariste Technologies Ltd.
AlveoGene Ltd.	CARTemis Therapeutics GmbH	ExeVir Bio B.V.
Amarna Therapeutics B.V.	CaSRevolution s.r.l.	Feldan Bio Inc.
AM-Pharma B.V.	Cellaion S.A.	Fibrocor Therapeutics Inc.
Amyl Therapeutics S.a.r.l.	Cmr CureDiab Metabolic Research GmbH	Flamingo Therapeutics Inc.
Ananda Immunotherapies	Coave Therapeutics S.A.	Focal Biosciences AG
Anavo Therapeutics B.V.	Confo Therapeutics N.V.	Forx Therapeutics AG
Araclon Biotech S.L.	Cumulus Oncology Ltd.	Gate2Brain S.L.
Arecor Therapeutics plc		Glox Therapeutics Ltd.



GlycoEra AG	Nucleome Therapeutics Ltd.	SurvivX B.V.
Iktos S.A.S.	OMass Therapeutics Ltd.	Synendos Therapeutics Inc.
Immunis Inc.	Oncode Institute	Tagworks Pharmaceuticals B.V.
iN Therapeutics Co. Ltd.	Oncomatrix Biopharma S.L.	TauC3 Biologics Ltd.
InSilicoTrials Technologies S.p.A.	Oniria Therapeutics S.L.	TES Pharma s.r.l.
Kernal Biologics Inc.	Origenis GmbH	Tessellate Bio B.V.
Kudo Biotechnology Inc.	Oryzon Genomics S.A.	Traverse Biotech Inc.
Kynos Therapeutics Ltd.	Pan Cancer T B.V.	Tribune Therapeutics AB
Ladder Therapeutics Inc.	PDC*line Pharma S.A.S.	Vaderis Therapeutics AG
Laverock Therapeutics Ltd.	PK Med S.A.S.	VarmX B.V.
LimmaTech Biologics AG	Pneumagen Ltd.	Vesper Bio ApS
Luminary Therapeutics Inc.	Pretzel Therapeutics Inc.	Viralgen Vector Core S.L.
Mabylon AG	Resolution Therapeutics Ltd.	Vivet Therapeutics S.A.S.
MC2 Therapeutics A/S	Rinri Therapeutics Ltd.	Ziphius Vaccines N.V.
Microviable Therapeutics S.L.	Rnatics GmbH	
Mikrobiomik Healthcare Company S.L.	RS Oncology LLC	
MiNA Therapeutics Ltd.	Sapient Therapeutics Ltd	
Minoryx Therapeutics S.L.	Senisca Ltd.	
MitoRx Therapeutics Ltd.	Sibylla Biotech S.p.A.	
Montis Biosciences B.V.	Simmunext Biotherapeutics B.V.	
MRM Health N.V.	SonoThera Inc.	
Muna Therapeutics	SparingVision S.A.S.	
Myricx Pharma Ltd.	SpliceBio S.L.	
NanoPhoria s.r.l.	StemSight Oy	
Noema Pharma AG	Step Pharma S.A.S.	
NUAgo Therapeutics Inc.	Storm Therapeutics Ltd.	

PRE-EVENT NETWORKING EXCURSIONS

Build stronger connections with CEOs and investors by joining a pre-event networking excursion (Sunday, May 12, 2024). These excursions are expected to sell out.



Txakoli Winery Tour

Spanish Basque Country is famous for txakoli, a sparkling white wine. Join Bio€quity delegates for a tasting at a local txakoli winery followed by a networking lunch.

Chillida Leku Museum Tour

This year is the 100th birthday of Eduardo Chillida, one of the most influential Spanish artists of the 20th Century, and a native of San Sebastián. Join Bio€quity delegates on an exclusive guided tour by the Chillida family of the Chillida Leku outdoor sculpture museum followed by a networking lunch.

9-hole Golf Scramble

Join Bio€quity delegates for a nine-hole scramble at Goiburu golf course, located in the Leitzarán Valley in Basque Country, followed by a networking lunch.

Pintxos Walking Tour

San Sebastián is famous for its pintxos bars, a bucket list experience for foodies around the world. Join Bio€quity delegates on a guided walking tour of Old Town, where you will stop to sample pintxos from some of the town's most famous bars.

Hosted by:




****Space is limited and requires advance registration****
Email conferences@biocentury.com for more information.

ATTENDING ORGANIZATIONS

3B Future Health Ventures	Alkapharmics	AstriVax
4Bio Partners	Ally Bridge Group	Atamyo Therapeutics
Abalos Therapeutics	Altitude Life Science Ventures	Atar Advisors
AbbVie Deutschland	AltruBio	Avant Bio
AbbVie Ventures	AlveoGene	Axoltis Pharma
Abingworth	Alveron Pharma	Azafaros
Abliva	Alveus Therapeutics	B7 Therapeutics
ACM Biosciences	Amarna Therapeutics	B7% Europe
Acousia Therapeutics	AM-Pharma	Bantam Pharmaceutical
Addio Partners	Amplify Therapeutics	Bartholomew Advisors
ADCendo	Amyl Therapeutics	BioBloC
Addex Therapeutics	AmyriAD Therapeutics	Biofidelity
Adiposs	Anaveon	BioGeneration Ventures (BGV)
Adva Biotechnology	AnavoTherapeutics	BioGlobal Consulting Group
advanceCOR	Angelini Ventures	BioInnovation Institute Foundation
Advent Life Sciences	Antag Therapeutics	BioInvent International
Advesya	Apices Soluciones	Bioqube Ventures
Agio Capital & Business Solutions	Araclon Biotech	Biosaxony Management
Aignostics	ARCH Venture Partners	Biotech Austria
Alder Therapeutics	Arecor Therapeutics	Biotheus
Alentis Therapeutics	ArgoBio Studio	BioVersys
Aleta Biotherapeutics	Ariceum Therapeutics	Biovision Ventures
Alia Therapeutics	Arthex Biotech	Bioxodes
Aliath Bioventures	Asceneuron	Bit Bio
Alira Health	Asociacin Centro de Investigacin Co	BlackRock



2023 highlights


 <p>MORE THAN 290 VCs</p> <p><i>from European, U.S. and Asian firms</i></p>	 <p>MORE THAN 600 BIOPHARMA EXECUTIVES</p> <p><i>including 330 CEOs + 150 CFO/CBO/COOs</i></p>	 <p>MORE THAN 170 PRESENTING COMPANIES,</p> <p><i>including 104 'Next Wave' newcos</i></p>
---	--	--



Bloomsbury Genetic Therapies	Dawn Biopharma	Flamingo Therapeutics
Blue Wave Therapeutics	Deep Science Ventures	Flanders Investment & Trade
Boehringer Ingelheim Venture Fund	Delin	Focal Biosciences
BOM	Diamyd Medical	Forbion
Brainomix	Dimericon Therapeutics	FoRx Therapeutics
Braintale	DiNAQOR	Frazier Life Sciences
Brandon BioCatalyst	Domain Therapeutics	FreeMind Group
Brandon Capital	Dorian Therapeutics	FutuRx
Broadview Ventures	Dr Lang Consulting	Gate2Brain
Caedo Oncology	Droia	Genicity
Calluna Pharma	Dualyx	Gilde Healthcare
Cambridge Innovation Capital	Earlybird Venture Capital	Gimv Germany Holding
Candel Therapeutics	EG 427	GLN-Bio Investments
Capital Grand Est	Egle Therapeutics	Global BioAccess Fund
CARTemis Therapeutics	Eir Ventures	Glox Therapeutics
CaSRevolution	Eli Lilly And Company	GlycoEra
Catalym	ENA Respiratory	GlycoTherapeutics
Catalyst Advisors	Encelta	Goodwin
CBT Advisors	Engimmune Therapeutics	Grey Wolf Therapeutics
CD3-KULeuven	EnteroBiotix	Grifols
CDR-Life	ENTEROME	Hadean Ventures
Cellaion	Epoqe Pharma	Harness Therapeutics
Certa Therapeutics	Epsilogen	HBM Partners
Chugai Venture Fund	EQT Life Sciences	HealthCap
Cinference	ESC	High-Tech Gründerfonds Management
Circio	Esobiotec	HollandBIO
Coave Therapeutics	Esperante Ventures	HSBC Innovation Bank
Columbus Venture Partners	Ethis	Hyloris Pharmaceuticals
Confo Therapeutics	Eurasanté	ICON
Cooley	Evariste	ICR Consilium
Coulter Partners	Evolution Life Science Partners	IKTOS
Covington & Burling	Evotec	Immunis
Crescendo Biologics	ExeVir Bio	Immuno Coaching Tx
Criteria Bio Ventures	F2G	iN Therapeutics
CTI Life Sciences Fund	FCF Fox Corporate Finance	Indaco Venture Partners
Cumulus Oncology	FCPM III Services	Inkef
Curadh MTR	Feldan Therapeutics	Innovestor Life Science
CureDiab Metabolic Research GmbH	Ferring Pharmaceuticals	InSilicoTrials
Curve Therapeutics	Fibrocor Therapeutics	Integra Therapeutics
Cytoki Pharma	FimmCyte	Invenis Biotherapies
Dania Therapeutics	Finnish Drug Discovery Center	Inveready Asset Management

invIOs	Lundbeckfonden Emerge	MitoRx Therapeutics
Invivo Partners	M Ventures	MiWEndo Solution
IONctura	M:M Bio	Molab.ai
Ipsen	Mabylon	Monograph
Jeito Capital	Macomics	Montis Biosciences
JJDC	MC Sciences	Monument Therapeutics
Johnson & Johnson	MC Services	MRM Health
JP Morgan	MC2 Therapeutics	MTS Health Partners
Kernal Biologics	McDermott Will & Emery	Myeloma Investment Fund
Kling Biotherapeutics	McKinsey & Company	MyricxBio
Kudo Biotechnology	McQuade Center for Strategic Research	NanoPhoria
Kurma Partners	MD Anderson	Neumirna Therapeutics
Kynos Therapeutics	Medicxi	New Rhein Healthcare Investors
Laverock Therapeutics	MEDiSTRAVA Consulting	NH Theraguix
Lead Discovery Center	Medix	NLC Health Ventures
Leerink Partners	Memo Therapeutics	Noema Pharma
Legacy Healthcare	Merck KGaA	Nordic Pharma
Leyden Labs	Mestag Therapeutics	NOVALIX
LifeArc	MetrioPharm	Novo Holdings
LiFT BioSciences	Microbiotica	NRW.BANK
Lightstone Ventures	Microviable Therapeutics	NUAgo Therapeutics
LimmaTech Biologics	Mikrobiomik Healthcare Company	Nucleome Therapeutics
Lingmed	Milano&Partners	Nutter McClennan and Fish
LISAvienna	MinervaX	Oculus
Longitude Capital	Minoryx Therapeutics	OMass Therapeutics
Luminary Therapeutics	Mironid	Oncode Accelerator
Lundbeckfonden BioCapital	Mission Therapeutics	Oncomatrix Biopharma

INDUSTRY SECTOR



Biotech


Private Equity/VC

Pharma

Consulting & Legal

Other

JOB FUNCTION



C-Suite


Exec.

Manager

Chairman, CEO, Managing Director, Partner

President, Vice President & Director

REGION



Europe

North America

Asia

Other



One Biosciences	Raya Therapeutic	SwedenBIO
Oniria Therapeutics	ReBio Pharma	Swedish Orphan Biovitrum
Optimum Strategic Communications	Rejuvenate Biomed	Syncona Investment Management
OrbiMed Advisers	Resolution Therapeutics	Syndivia
Origenis	Rewind Therapeutics	Synendos Therapeutics
Orikine Bio	Rinri Therapeutics	Synklino
Orionis Biosciences	River BioMedics	SynOx Therapeutics
Orthros Medical	RNATICS	Tagworks Pharmaceuticals
Oryzon Genomics	Roche Venture Fund	Taiho Ventures
Otsuka Pharmaceutical Companies US	RS Oncology	Takeda Ventures
Outrun Therapeutics	RV Invest	TauC3Biologics
Oxford Science Enterprises	Sanofi Ventures	Teitur Trophics
Oxolife	Scandion Oncology	Telomere Therapeutics
Pan Cancer T	Scendea	TES Pharma
Panakes Partners	Scenic Biotech	Tesi
Panmure Gordon	Secarna Pharmaceuticals	Tessellate BIO
PDC*line Pharma	SENISCA	TetraKit Technologies
PEP-Therapy	Serna Bio	The Provincial Council of Gipuzkoa
PER	Seroba	Thermo Fisher Scientific
Perseo Pharma	Sibylla Biotech	Thermosome
Pfizer	Sidley Austin	Thuja Capital Management
Pharmacosmos	Silver Arrow	Tolremo Therapeutics
PhoreMost	Simmunext Biotherapeutics	Traverse Biotech
Pioneering Medicines	SIX Swiss Exchange	Treefrog Therapeutics
Piper Heartland Healthcare Capital	Sofinnova Partners	Tribune Therapeutics
PK Med	SonoThera	Trill Impact
Pledge Therapeutics	Sound Bioventures	Trophic Communications
Pneumagen	SparingVision	UBS
Precision BioSearch	SpliceBio	UCB Biopharma UK
Pretzel Therapeutics	SR One	UCB Ventures
Private Equity Recruitment Ltd. (PER)	StemSight	Umlaut.bio
Project Cypress	Step Pharma	Unicycive Therapeutics
Pulnovo Medical	STipe Therapeutics	Univercells
Pureos Bioventures	Storm Therapeutics	Urania Therapeutics
Purespring Therapeutics	Sulis	Vaderis Therapeutics
QPMind	SunRock Biopharma	Van Lanschot Kempen
Queen Mary University of London	Sunstone Life Science Ventures	VarmX
RA Capital Management	SurvivX	V-Bio Ventures
Rambam	SV Health Investors	Versant Ventures



Vertex Ventures
 Vesper Bio
 VIB
 Villus Therapeutics
 Viralgen
 Vivet Therapeutics
 Vivo Capital
 WEHI Ventures
 Wellington Partners LS VC Mgmt
 XGEN Venture
 Ysios Capital
 YVC Collective
 Zai Lab
 Ziphilus Vaccines
 Zyvrant Pharmaceuticals

BONUS CONTENT



Join Jeff Cranmer, Executive Editor and host of *"BioCentury This Week,"* for this exclusive "Bio€quity Europe" preview episode:

Week of May 6

Bio€quity Europe Preview

BioCentury This Week features in-depth conversations with BioCentury's editorial team on current topics in biopharma. Available on Apple, Spotify, YouTube or your podcast channel of choice.

partneringONE® opens April 8, 2024

Update your company and personal profiles within 24 hours of registering and prepare to start scheduling meetings in partneringONE. Don't forget, this year's event includes two bonus days of digital partnering, May 22-23, 2024.

For assistance with partneringONE, please contact:

partneringteam@informaplcn.microsoft.com





PRELIMINARY AGENDA

**subject to change*

SATURDAY, MAY 11, 2024

Recommended arrival into San Sebastián, Spain. [CLICK HERE TO VIEW THE OFFICIAL BIO€QUITY EUROPE TRAVEL GUIDE](#)

SUNDAY, MAY 12, 2024

11:00 AM – 4:00 PM

PRE-EVENT NETWORKING EXCURSIONS

**Space is limited, please register in advance.*

- Pintxos Walking Tour
- Txakoli Winery Tour
- 9-hole Golf Scramble
- Chillida Leku Museum Tour

5:00 PM – 6:30 PM

REGISTRATION & NETWORKING

**Join us at the San Telmo Museum for our 2024 Welcome Reception & 4th BioCentury "Scene Setter" opening plenary.*



6:30 PM – 7:30 PM

BIOCENTURY'S 4TH SCENE SETTER PANEL

Continuing a long Bio€quity Europe tradition, BioCentury's Scene Setter panel will set the stage for this year's conference, featuring some of Europe's leading investors and biotechs, in a dynamic conversation that engages the audience and highlights this year's theme: rising above the noise.

Session Chair: Simone Fishburn, Ph.D., VP and Editor in Chief, BioCentury Inc.

Panelist: Hakan Goker, Ph.D., Managing Director & Head, M Ventures
Joël Jean-Mairet, Ph.D., Managing Partner, Ysios Capital
Vanessa King, Biotech CEO, Founder and Board Member
Antoine Papiernik, Chairman & Managing Partner, Sofinnova Partners

7:30 PM – 8:30 PM

NIGHT CAP COCKTAIL NETWORKING RECEPTION



MONDAY, MAY 13, 2024

7:00 AM – 9:00 AM	REGISTRATION & NETWORKING BREAKFAST *at the Kursaal Elkargunea Center
7:30 AM – 8:30 AM	NETWORKING BREAKFAST FIRESIDE CHAT: VOICES, VALUES AND VENTURE LESSONS IN LEADERSHIP <i>Kate Bingham is not only one of biotech's most prominent female investors, but one of the few leaders in the industry to become a household name, having led the U.K.'s vaccine taskforce during the pandemic and steered its highly successful COVID-19 vaccine program. As managing partner of SV Health Investors she has created numerous companies, and pioneered the launch of the Dementia Discovery Fund. In this Fireside Chat, Bingham will discuss the drivers of successful leadership, how to walk the tightrope of diplomacy and effective management, and what she hopes to see in the next generation of VC investors.</i> <u>Session Chair:</u> Simone Fishburn, VP & Editor in Chief, BioCentury Inc. <u>Emcees:</u> Rabab Nasrallah, Ph.D., Principal, Earlybird Venture Capital, & Member, Breaking 7% Paula Olazábal, Partner, Ysios Capital and Member, Level 20 Spain Committee <u>Panelist:</u> Kate Bingham, Managing Partner, SV Health Investors
8:40 AM – 8:45 AM	OPENING BELL CEREMONY Hosted by: Euronext Paris S.A.
8:45 AM – 9:00 AM	WELCOME TO BIOEQUITY EUROPE 2024 Join BioCentury, EBD Group, and the San Sebastián Regional Hosts to celebrate the official opening of the 24th BioEquity Europe.
9:00 AM – 6:00 PM	2ND ANNUAL POSTER SPOTLIGHT: KEY TRANSLATIONAL OPPORTUNITIES FROM EUROPE <i>The rising flow of translational innovations from academic centers makes it more important than ever to connect top translational researchers with the networks required to turn discoveries into drugs. Likewise, innovative biotechs are pushing the frontiers of translational science. This poster session features innovators from the European academic ecosystem whose research has commercial potential, alongside posters from BioEquity Pre-Seed and Presenting Companies that have already begun their journey.</i>
9:00 AM – 7:00 PM	C-LEVEL PARTNERING MEETINGS
9:00 AM – 9:45 AM	CONFERENCE REPORT KEYNOTE: HOW TO RISE ABOVE THE NOISE <i>Recent successful IPOs, business development and M&A activities have boosted optimism in the biotech community. Yet, an increasing number of biotechs are competing for available wallets and partnership opportunities. How can biotechs successfully differentiate and 'rise above the noise'? And how can investors and business development teams deploy their capital efficiently, identifying future 'winners' early? Insights Partner McKinsey & Company debuts its fifth annual report on European biotech, with an analysis of key trends in the biotech investment landscape (the 'noise'), and a study of companies that have risen above the noise with a deep dive on a selection of European hubs. Advanced access to McKinsey's 2024 Biotech Report will be available exclusively to all BioEquity delegates.</i> <u>Session Chair:</u> Alexandra Zemp, PH.D., Partner, McKinsey & Company
9:45 AM – 10:45 AM	TALENT SHOWCASE: IS YOUR BOARD RISING ABOVE THE NOISE? <i>Good boards will not simply make noise, they'll help their companies rise above the noise. But that takes the right combination of skills, perspectives and personalities. Embracing diversity of thought and experience means making time and room for discussion, but efficiency of decision-making is paramount for companies under pressure. This panel will discuss how to assemble, manage, and adapt the right board to help companies differentiate and manage through a challenging era.</i> <u>Panelists:</u> Roel Bulthuis, Managing Partner, Syncona Bianca Coulter, CEO, Coulter Partners Rachel Mears, Partner, Jeito Capital Naveed Siddiqi, M.D., Senior Partner, Novo Holdings



10:00 AM – 6:00 PM **PRESENTING COMPANY ROADSHOW TRACKS**

10:45 AM – 11:15 AM **MORNING NETWORKING BREAK**

11:15 AM – 12:00 PM **CONCURRENT SESSIONS**

SESSION 1:

R&D SHOWCASE #1: SCALING UP EUROPE'S ACADEMIC ENGINE IN CELL AND GENE THERAPY

In the world of cell and gene therapies, strong, early clinical data from small academic studies have repeatedly catalyzed paradigm shifts that reverberate across industry. European physician-scientists have been at the forefront of several breakthroughs, including CAR T cells for autoimmunity. But is that transformational value being captured by local ecosystems? What is the playbook for fostering and commercializing the translational leaps by Europe's academic KOLs?

SESSION 2:

PREPARING FOR THE SEA CHANGE IN EUROPEAN PHARMA LEGISLATION

Europe is undergoing the biggest remaking of its pharmaceutical legislation in a generation, which will influence how investors and companies think about the European commercial market. This expert panel will describe the potential impact on biopharma companies, and identify ways the industry can shape the direction of the legislation as it moves through the political process.

Session Chair: Maarten Meulenbelt, Partner, Sidley

12:00 PM – 12:45 PM **CONCURRENT SESSIONS**

SESSION 1:

R&D SHOWCASE #2: DERISKING DEMENTIA

From multi-omics to clinical phenotyping, rising above the noise in neuroscience means derisking therapies with human data, deploying biomarkers and carefully matching targets to therapeutic modalities. With drug development for dementia picking up steam, this panel will discuss what it takes to balance risk and opportunity across these parameters to create a product profile that stands out from the pack.

Session Chair: Arno de Wilde, Ph.D., Director, EQT Life Sciences

Panelists: Laurence Barker, Ph.D., Partner, SV Health Investors, Dementia Discovery Fund
Johanna Fälting, Chief Research Officer, BioArctic AB

SESSION 2:

BUILDING SUCCESSFUL SYNDICATES

As biotech CEOs look to rise above the noise, building a winning investor syndicate is essential. Deep pockets are important, but investors also must align around capital requirements, key de-risking steps, and continued insider support for the next financing round. In Europe, where syndicates are generally smaller, the need for alignment is more acute. This workshop brings together VCs, institutional investors and board directors to share lessons learned for syndicate success.

Panelists: Andrew Lam, PharmD., Managing Director, Head of Biotech, Ally Bridge
Greg Parekh, Ph.D., Managing Partner, New Rhein Healthcare

12:45 PM – 1:00 PM **NETWORKING LUNCH**

2:00 PM – 2:45 PM **CONCURRENT SESSIONS**

SESSION 1:

13TH CEO BOOT CAMP: COMMUNICATE, COMMUNICATE, COMMUNICATE

Competition for capital and partnerships is fierce. Communicating your value proposition and how you are differentiated must be Job 1 for the biotech C-suite. Are Europe's biotech leaders succeeding in this crowded environment? BioEquity's annual CEO boot camp lays out what European chief executives must do to stand out against their international competitors.

Session Chair: Carole Nuechterlein, Head, Roche Venture Fund

Panelist: Soren Moller, Ph.D., Managing Partner, Novo Seeds



SESSION 2:

DEALMAKERS SHOWCASE: HOW TO GRAB THE ATTENTION OF PHARMA BD&L EXECS

With patent cliffs fast approaching, pharmas and big biotechs are on the hunt for assets to shore up their near-term revenues as well as their longer-term pipelines. At the same time, the big players are inundated with pitches from small biotechs trying to attract a flagship partner. This panel focuses on what biotechs must do to rise above the noise to attract their attention.

Panelists: Khatareh Ahmadi, Ph.D., Head of Search and Evaluation, BD&L, Europe and Middle East, MSD
Paul Peter Tak, M.D., Ph.D., President & CEO, Candel Therapeutics
Nathalie Ter Wengel, European Lead, Worldwide Business Development, Pfizer

2:45 PM – 3:30 PM

CONCURRENT SESSIONS

SESSION 1:

FINANCING TECHBIO – CONVERGING TECH AND BIO TO POWER BIOTECH INTO THE ERA OF AI

There's no "If" anymore, it's all "when" -- everyone now has an AI or machine learning story in biotech, but there's still a lot of noise to know where the value lies. And as technologies emerge that can drive radical improvements, new investment models will be needed to convert them into viable companies. Some traditional tech and biotech VCs are coming together to syndicate, others are building funds or firms from the ground up. This panel will discuss the paths to value creation as biotech enters the era of AI.

Panelists: John Cassidy, General Partner, Kindred Capital
Edward Kliphuis, Partner, Sofinnova Partners
Rabab Nasrallah, Ph.D., Principal, EarlyBird Venture Capital

SESSION 2:

7TH WEST-EAST ROUNDTABLE: WHAT'S NEEDED TO GROW CROSS-BORDER DEAL FLOW

The surge in East-West dealmaking has shown Asia can be a player in global innovation networks. The challenge is to create more visibility for Asian assets that are not yet on the radar in Europe and the U.S., and for potential partners to access the Asia-Pacific markets. In BioEquity's seventh West-East Roundtable, dealmakers from both sides will identify what will be needed to maintain deal flow in both directions.

Session Chair: Josh Berlin, Head of Corporate Alliances and Business Development, BioCentury Inc.
Panelists: Vishal Doshi, CEO, AUM BioSciences
Franck Le Deu, Senior Partner & Co-Leader of Asia Life Sciences Practice, McKinsey & Company
Marietta Wu, M.D., Ph.D., Managing Director, Quan Capital
Shanshan Xu, Ph.D., VP, External Innovations, BioNTech

3:30 PM – 4:00 PM

AFTERNOON NETWORKING BREAK

4:00 PM – 5:15 PM

REGIONAL HOST SESSION: SPOTLIGHT ON SPANISH BIOTECH

PART 1:

CEO PERSPECTIVES: VENTURE CAPITAL AS A GROWTH DRIVER FOR SPAIN'S LIFE SCIENCES SECTOR

Spain's standing in the life sciences has risen over the past decade-plus as its high quality of science offers promise for biomedical solutions, but it's taken time to create companies and attract specialized investors. In this session, local leaders discuss the evolution of the ecosystem, the challenges ahead, and how to attract international VCs to Spain.

Session Chair: Ion Arocena, CEO, Asebio
Panelist: Joan Perelló Bestard, Ph.D., CEO, Sanifit
Valerie Vanhooren, Ph.D., Co-Founder & CEO, Ona Therapeutics



PART 2:

THE LIFE SCIENCES REVOLUTION IN GIPUZKOA: WHAT'S NEXT?

With a longstanding industrial heritage, the province of Gipuzkoa has emerged as a growing player in the Spanish life sciences ecosystem. This panel will discuss how life sciences in Gipuzkoa can become a driver of the local economy, backed by a local government committed to making the sector attractive to international investors and human talent.

Session Chair: Paula Olazabal, Partner & Head of ESG, Ysios Capital

Panelist: Javier García, Chairman, Viralgen
 Estibaliz Hernández, Deputy Minister of Technology, Innovation and Digital Transformation, Basque Country
 Ane Insausti, Deputy of Economic Development and Strategic Projects, Gipuzkoa
 Gurutz Linazasoro, CEO, Vive Biotech
 Arantza Muriana, Co-Founder, R&D Director & CEO of USA, Biobide

5:15 PM – 6:15 PM

FIRESIDE HAPPY HOUR CHAT

6:15 PM – 10:00 PM

NETWORKING RECEPTION - MIRAMAR PALACE

Join BioCentury, EBD Group, and the BioEquity Europe 2024 Regional Hosts for an evening of local food, wine, and networking at Miramar Palace. Built in 1893 at the request of Queen María Cristina, the palace sits on a hill above La Concha Bay and Santa Clara Island.



6:15 PM – Bus departures from the Kursaal

7:00 PM – Networking Reception

TUESDAY, MAY 14, 2024

7:30 AM – 8:30 AM

3RD ANNUAL FUN RUN

Rise and shine early and join industry colleagues on a guided fun run through San Sebastián. All levels welcome. Sponsored by the "BioCentury This Week" podcast -- Take BioCentury on the run.

Team Captains: Arthur Franken, General Partner, Gilde Healthcare
 Erica Whittaker, Ph.D., VP & Head, UCB Ventures

8:00 AM – 5:00 PM

C-LEVEL PARTNERING MEETINGS

8:00 AM – 9:00 AM

REGISTRATION & NETWORKING BREAKFAST

9:00 AM – 3:00 PM

2ND ANNUAL POSTER SPOTLIGHT: KEY TRANSLATIONAL OPPORTUNITIES FROM EUROPE

The rising flow of translational innovations from academic centers makes it more important than ever to connect top translational researchers with the networks required to turn discoveries into drugs. Likewise, innovative biotechs are pushing the frontiers of translational science. This poster session features innovators from the European academic ecosystem whose research has commercial potential, alongside posters from BioEquity Pre-Seed and Presenting Companies that have already begun their journey.

9:00 AM – 3:00 PM

PRESENTING COMPANY ROADSHOW TRACKS



9:30 AM – 10:15 AM

CAPITAL MARKETS SHOWCASE: GETTING ATTENTION IN A BUYERS' MARKET

As biotech progresses toward a market recovery, investors are looking for new opportunities. But hundreds of public and private companies are urgently looking to raise new capital after the long bear market, and the reality is that many will not be chosen. This investor-led session will identify the boxes that biotechs much check to attract investor attention in a buyers' market.

Session Chair: Erica Whittaker, Ph.D., VP & Head, UCB Ventures

Panelist: Nilesch Kumar, Ph.D., Wellington Management
Giovanni Mariggi, Ph.D., Co-Founder & Partner, Medicxi
Ksenija Pavletic, Partner, Jeito Capital
Sophie Stegen, Head of Listing Belgium, Euronext N.V.

10:15 AM – 11:00 AM

CONCURRENT SESSIONS

SESSION 1:

R&D SHOWCASE #3 - EXPANDING THE HORIZONS OF PRECISION MEDICINE

As precision medicine takes tentative steps beyond cancer, success will require learning new lessons. True genetic drivers are fewer in number in autoimmunity and neurology, yet differences in biology must underly disease heterogeneity. This session will examine the types of biomarker approaches that will be key to stratifying patients and identifying surrogate endpoints, and what other factors may come into play as the competition heats up outside of oncology.

Session Chair: William Maier, Ph.D., VP & Head, Center for Rare Disease, ICON

Panelists: Brian Liu, M.D., Managing Director, Longitude Capital
Ilise Lombardo, M.D., CEO, Noema Pharma
Joep Muijers, General Partner, Gilde Healthcare
Haru Sugino, Ph.D., Global Head, Search and Evaluation, Global Business Development, Otsuka Pharmaceutical

SESSION 2:

CAPITAL MARKETS WORKSHOP: WORKING WITH NEW SOURCES OF CAPITAL

Sovereign wealth, family offices and other non-traditional investors are exploring biopharma as a way to diversify their portfolios and achieve social goals. But the biotech timeline and a preference for direct investment present challenges to both venture funds and emerging companies. This session explores how investor syndicates and biotechs should be building these new relationships.

Panelists: Masha Stromme, Ph.D., Co-Chair, PAACS Invest
Martin Turner, Ph.D., Associate Director, Policy, Public Affairs & Investor Relations, BIA
Nico Vandervelpen, Managing Partner, Bioqube

11:00 AM – 11:30 AM

MORNING NETWORKING BREAK

11:30 AM – 12:30 PM

CONCURRENT SESSIONS

SESSION 1:

8TH ANNUAL BIO€QUITY EUROPE PRE-SEED SHOWCASE

Bio€quity continues to showcase new ideas. Watch selected pre-seed companies present to distinguished Bio€quity Europe "judges," who provide high-level feedback on each entrepreneur's pitch, business plan and strategy.

SESSION 2:

LEARNINGS ON HOW TO RISE ABOVE THE NOISE

In this special breakout session, Insights Partner McKinsey & Company gathers a panel of biotech investors from both the VC as well as pharma BD side to discuss lessons learned from recent dealmaking – what excites them and what doesn't? Are there specific success factors for biotechs to differentiate vs peers?



12:30 PM – 1:30 PM

NETWORKING LUNCH

1:30 PM – 2:30 PM

CONCURRENT SESSIONS

SESSION 1:

R&D SHOWCASE #4: CAMBRIAN EXPLOSION IN ADCs; WHAT ARE EUROPE'S LEVERS TO RISE ABOVE THE NOISE?

As competition escalates in ADCs, companies are exploring new targets, linkers, payloads and indications, and improving the science behind ADC manufacturing. This panel will discuss what the next generation of ADCs should be, what advantages European players can leverage to draw investors, and how the ADC landscape in Europe will fare against steep competition from the U.S. and Asia.

Panelists: Jan Anderl, Ph.D., Global Head, ADCs, Merck KGaA
Christoph Broja, Managing Director, EQT Life Sciences

SESSION 2:

R&D SHOWCASE #5: HOW WILL EUROPE USE ITS VAST BIOMEDICAL DATA LAKE TO POWER DRUG FINDING AND DRUG DEVELOPMENT?

Europe's integrated healthcare systems and investments in innovative biobanks have created some of the richest biomedical data repositories in the world. The rapid acceleration of AI now promises to turn reams of data into actionable insights. This session will discuss how innovators are reducing AI to practice for target discovery and trial design using Europe's data hubs, and whether signal-finding this way can stand out against a sea of noise in this rapidly moving field.

Session Chair: Selina Koch, Ph.D., Executive Editor, BioCentury Inc.
Panelists: Steve Gardner, Ph.D., C-founder & CEO PrecisionLife

2:30 PM – 3:15 PM

3RD FUTURE LEADERS OF EUROPEAN INVESTMENT

Once again, BioEquity Europe closes by looking ahead. How will the next generation of European financiers rise above the noise? How are they planning to identify, create and build successful innovator companies, and what are they aiming to do differently? In this closing Future Leaders plenary, up-and-coming VCs describe their strategies for raising and deploying capital in Europe.

Session Chair: Karen Wagner, Ph.D., Managing Partner, Ysios Capital
Panelists: Gabriela Ecco, Senior Associate, +ND Capital
Anne Grahl, Associate, Pureos Bioventures

3:15 PM – 4:00 PM

CLOSING RECEPTION & HAND-OFF CEREMONY TO 2025 REGIONAL HOSTS

Join BioCentury and EBD Group for a final round of networking as we celebrate the conclusion of BioEquity Europe 2024 in San Sebastián and hand over the reins to the Regional Hosts of BioEquity Europe 2025.

4:00 PM – 10:00 PM

ECOSYSTEM TOUR & RECEPTION

Join BioCentury, EBD, and the San Sebastián Regional Host Committee for an exclusive tour of the biosciences ecosystem of Gipuzkoa. Visit BIC Gipuzkoa, Viralgen, Vive Biotech, and Mondragon Corp. Afterwards, join the AseBio Investor Day Reception for a final round of networking. Transportation provided. Space is limited, RSVP in advance.



4:00 PM – Buses depart the Kursaal

4:30 PM – 7:30 PM Ecosystem Tour

8:15 PM – AseBio Investor Day Networking Reception



Let us help you AND your team members prepare for your 1x1 meetings

Starting April 1, 2024, receive complimentary access to BioCentury's business intelligence platform. Research pipelines, financings, deals and exclusive analysis to help you prepare for BioEquity meetings with potential investors and partners.



Want to learn more?

[Schedule an online session](#)

with BioCentury for tips on how to use BCIQ to prepare for BioEquity Europe, and other industry conferences.



EVENT ORGANIZERS

BIOCENTURY BioCentury gives biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; and industry-leading business intelligence, and global events. www.biocentury.com

EBD GROUP EBD Group is the leading partnering firm for the global life science industry.

Our mission is to facilitate the critical, strategic connections that drive life science dealmaking.

We specialize in bringing people together, whether face-to-face at one of our leading global life science partnering events powered by partneringONE, or virtually through our online community of dealmakers and thought-leaders. www.ebdgroup.com

INSIGHTS PARTNER

McKinsey & Company McKinsey is a global management consulting firm committed to helping organizations accelerate sustainable and inclusive growth. We work with clients across the private, public, and social sectors to solve complex problems and create positive change for all their stakeholders. We combine bold strategies and transformative technologies to help organizations innovate more sustainably, achieve lasting gains in performance, and build workforces that will thrive for this generation and the next. www.mckinsey.com

FOUNDING SPONSOR

Sofinnova partners Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.

Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. www.sofinnovapartners.com

REGIONAL HOST COMMITTEE



Gipuzkoako
Foru Aldundia
Diputación Foral
de Gipuzkoa

The Provincial Council of Gipuzkoa is responsible for governing and administering the province of Gipuzkoa. Its President is elected by the General Assembly and is responsible for implementing the programme of the government, which is made up of provincial councillors appointed by the President. The General Assembly is the governing body of the Provincial Council and is responsible for setting the guidelines for and aims of the provincial government's actions. www.gipuzkoa.eus/web/council

YSIOS CAPITAL Ysios Capital is a leading life sciences investor financing highly innovative companies worldwide fostering a positive impact on patients and society. ysioscapital.com

R&D SESSION SPONSOR



ICON is the world's leading clinical research organisation, powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing a comprehensive suite of outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives.

Our outsourcing models can be adapted to suit small local trials to large global programs, including full service, standalone services, FSP and full asset development.

With headquarters in Dublin, Ireland, ICON employs approximately 41,150 employees in 113 locations in 53 countries. www.iconplc.com



TALENT SHOWCASE SPONSOR



JJDC is the strategic corporate venture arm of Johnson & Johnson (J&J) and is part of the Johnson & Johnson Innovation (JJI) team. JJDC was established more than 50 years

ago and is the longest-running corporate VC firm. We invest in medtech and biotech companies of all stages (NewCo formation, seed, series A and beyond, PIPEs, etc.). We are a committed long-term investor because our success is defined by helping develop innovation that improves patient outcomes. Over the last five decades, JJDC has invested billions of dollars in hundreds of companies and onboarded several into the J&J portfolio.

njinnovation.com/venture-investing-jjdc/year-in-review

NETWORKING BREAK SPONSOR



We are the leading retained search and recruitment specialists for private markets professionals. We work across investment strategies, in-house functions and

geographies. Whether you are building your team or seeking a vital strategic hire, we go to extraordinary lengths to identify and attract exceptional professionals for private equity, venture capital, private credit, secondaries and real assets. Every day we bring people together who will shape the future of this dynamic, international industry. www.per-people.com

PRE-EVENT NETWORKING EXCURSIONS HOSTS



Columbus Venture Partners is a Spanish independent venture capital that brings a unique approach for investing in outstanding early-stage and high growth opportunities in the life science industry of Spain.

Our team includes solid and internationally experienced investment professionals with a deep scientific, medical and business development background combined with a proven experience in building and investing in companies to accelerate their commercialization.

The combination of industry possibilities and investment experience will provide Limited Partner investors in the Fund a level of professionalism and deep expertise that is essential for success in this field. columbusvp.com

PRECISION BIOSEARCH Founded in 2020, Precision BioSearch provides a distinctive personalized service, recruiting top-tier talent for investor-backed, early-stage biotech ventures, from Board to C-suite and VP levels.

Our expertise lies in navigating the competitive landscape of next-generation therapeutics, crafting leadership teams of visionary experts who inspire and drive innovation forward.

Precision BioSearch employs a rigorous, agile methodology to expedite critical hiring, empowering organizations to scale swiftly and confidently. With expert proficiency spanning every stage of the recruitment process, our extensive relationships, networks, and impactful science-led communication consistently yields exceptional outcomes for investors and their portfolio companies. precisionbiosearch.com



**OXFORD
FINANCE**

Oxford Finance delivers flexible financial solutions to healthcare and life sciences companies worldwide.

Our capital provides clients with the fuel needed for innovation and growth. oxfordfinance.com



Viralgen is a CDMO that supports development through large-scale commercial production of cGMP certified adeno-associated virus

(AAV) for cell and gene therapies. Based in San Sebastián, Spain the company operates as an independent subsidiary of AskBio, which is a wholly owned subsidiary of Bayer AG. Viralgen offers the Pro10™ based suspension platform, a technology licensed from AskBio found to increase scalability, performance, and yield of AAV therapies. The company's state-of-the-art facilities include a clinical facility with 250 L and 500 L bioreactors and a commercial facility consisting of three modules, each having three cGMP suites with capacities of >2,000 L. viralgenvc.com

SPONSORS



Ally Bridge Group is a global healthcare manager focused on high-impact life science innovation across private and public markets. Founded in 2013 by Frank Yu, Co-Chief Executive Officer and Co-Chief Investment Officer, the firm manages assets from offices in New York and Hong Kong.

Our mission is to generate superior risk-adjusted returns for investors while seeking to address unmet medical needs. We aim to achieve this by blending deep scientific and clinical research with financial and capital markets expertise. ally-bridge.com



ASE BIO Association Española de Bioempresas
 ASEBio, the Spanish Bioindustry Association, brings together and represents the interests of companies, associations, foundations, universities and technology and research centres that work in the field of biotechnology in Spain.

We collaborate closely with regional, national and European governments, as well as with social organisations that are committed to science and the use of biotechnology to improve people's lives and promote environmental sustainability, economic development and high value-added employment.

Over the past 25 years, we have been working to bring about positive political and economic changes that foster and drive development of the Spanish biotechnology sector. We are committed to the use of biotechnology to improve quality of life and promote environmental sustainability, economic development and qualified jobs. www.asebio.com/en



BII offers entrepreneurially-minded researchers or anyone with a research-based idea help

to bring interdisciplinary ideas to life and research to market. We offer state-of-the-art facilities and various funding opportunities, as well as partnerships and programs with technical, scientific and commercial experts. Our main focus is health tech, bio-industrials and therapeutics. We envision that strong collaborations, a passion for science, and an open mind will foster research-based innovation and viable start-ups. BII does not work for profit but for the benefit of human welfare and society around the globe. bii.dk



Bioqube Ventures is a specialist life sciences investment firm founded in 2016. The team consists of investment professionals, sector experts and serial entrepreneurs that have a proven track record in successfully building and leading companies on their growth

paths. In 2020, Bioqube Ventures launched the Bioqube Factory Fund I, with a focus on the discovery and development of new therapeutic platforms and assets. With a diversified investment strategy, including a venture creation model and industry guidance through selected strategic partnerships, Bioqube Ventures will exclusively invest in the most promising innovative science in Europe and beyond. www.bioqubeventures.com



Boehringer Ingelheim
 Created in 2010, the Boehringer Ingelheim Venture Fund GmbH (BIVF) invests in ground-breaking companies to drive innovation in

biomedical research. BIVF is searching for significant enhancements in patient care through pioneering science and its



Candel is a clinical stage biopharmaceutical company developing multimodal biological immunotherapies to help fight cancer. Candel's two multimodal

biological immunotherapy platforms are based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs. CAN-2409, the lead adenovirus platform product candidate is in phase 2 and phase 3 trials in lung, pancreatic, and prostate cancers. CAN-3110, the lead HSV platform product candidate is in an investigator-sponsored phase 1 trial in recurrent high-grade glioma (HGG). Candel's enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for cancer. www.candeltx.com



Coulter Partners provides leadership

consultancy to Life Sciences, Health and Technology innovation businesses globally. We build teams that change the world and create a better future. Over 20 years we have delivered on 1000s of assignments across the USA, Canada, UK/Europe, and APAC, advising companies and investors on how to shape and hire their boards and leadership teams. We strongly impact value and growth. Our 120 experts operate uniquely as one global team. With our track record, AI, bespoke systems and wealth of data, we fuel the ability of investors, boards and executive teams to deliver value from innovation. www.coulterpartners.com



EQT
 Life Sciences

EQT Life Sciences was formed in 2022 following the integration of LSP, a leading European life sciences and healthcare venture capital firm, into

the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs the smartest inventors who have ideas that could truly make a difference for patients. eqtgroup.com



EURONEXT
10 YEARS SINCE IPO

Euronext is the leading pan-European market infrastructure and plays a key role at the heart of Europe's financial markets. We operate regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal, connected via a single trading technology offering access to all financial instruments across our markets. We provide custody and settlement services through central securities depositories in Denmark, Italy, Norway and Portugal, and clearing through our CCP in Italy. With our unique federal model as a foundation, Euronext is building the leading market infrastructure in Europe to shape capital markets for future generations. euronext.com



Gilde Healthcare is a specialized healthcare investor managing over €2.6 billion across two fund strategies: Venture & Growth and Private Equity. The Venture & Growth fund of Gilde Healthcare invests in fast growing companies active in therapeutics and health tech, based in Europe and North America. For more information, visit the company's website at www.gildehealthcare.com



Invest in Spain is an executive division of ICEX Trade and Investment, a publicly owned business-oriented entity of the Ministry of Economy, Trade and Business's Secretary of State for Commerce. www.investinspain.org/en/index



Jeito Capital is a global leading Private Equity company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients' access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States. www.jeito.life



M Ventures is the strategic, corporate venture capital fund of Merck KGaA, Darmstadt, Germany. We invest in Biotechnology and Technology, covering the areas of Healthcare drug development, Life Science tools, Electronics and Frontier Technology & Sustainability.

We invest into visionary companies that find new ways to: treat the most challenging diseases, empower scientists with cutting-edge research and development tools, develop new solutions that change the way in which information is accessed, stored, processed, and displayed and address some of the most complex challenges in sustainability and technology convergence. www.m-ventures.com



Medicxi is an international investment firm focused on the life sciences sector. It was established in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs. Medicxi is currently investing out of its most recent early-stage and late-stage funds and, additionally, continues to manage the Index Ventures life sciences portfolio. www.medicxi.com



MSD

For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. www.msd-uk.com



Health Partners

MTS Health Partners is a leading healthcare-dedicated investment bank that provides strategic and financial advice to the global healthcare industry. Since 1999, MTS has offered clients strategic and M&A advisory services and equity and structured financing expertise, and has executed 282 transactions representing over \$121 billion of value. In 2023, MTS secured the second-highest total M&A deal value and tied for third in total M&A deal count for biotech acquisitions valued at \$1+ billion, according to BioCentury. www.mtspartners.com



NEW RHEIN
HEALTHCARE INVESTORS

New Rhein Healthcare Investors, headquartered in Philadelphia, PA, is a dynamic life sciences-focused venture capital fund. Distinguishing itself by applying a private equity business model to venture capital investing, New Rhein strategically targets assets with proven clinical safety and efficacy.



At the core of New Rhein's investment strategy is a commitment to actively manage the value creation process. This involves taking substantial stakes in a select number of companies to enable a concentrated focus on successful product development and commercialization, while mitigating science-based risks.

New Rhein's team is comprised of former senior executives from renowned pharmaceutical companies, who bring industry-specific expertise to each deal. Steering the fund's deal-making, due diligence, and management decisions, their support allows New Rhein to sustainably scale businesses, ensuring the delivery of value to patients, payors, strategic acquirers, and investors. www.newrhein.com



Novo Holdings is a holding and investment company, responsible for managing the operating and financial assets of the Novo Nordisk Foundation.

Headquartered in Copenhagen and wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder in Novo Nordisk and Novozymes and manages an investment portfolio with a long-term return perspective. The Novo Holdings Investment Portfolio is comprised of Life Science Investments and Capital Investments. We aspire to be a leading responsible investor, recognized for delivering strong financial returns and positive societal impact. Novo Holdings operates from offices in Copenhagen, London, Boston, San Francisco, Singapore and Shanghai. As of year-end 2021, Novo Holdings had total assets of \$106 billion.

www.novoholdings.dk



Nutter, McClennan & Fish advises biotechnology companies and investors. We provide timely,

pragmatic guidance to strategic buyers looking to capitalize on market opportunities, investors seeking to expand their presence, and companies looking for experienced counsel to guide them through the complexities of a transaction. We have a proven track record of successfully protecting intellectual property assets. We help clients unlock the value of their IP, creating revenue streams from licensing and sales. We also develop IP strategies which determine what innovations should be protected or bolstered and the ones to be licensed or abandoned for optimal return on investment.

www.nutter.com

Roche Venture Fund

Connecting Innovation to Value

We are the corporate venture fund of Roche, a global leader in bringing medicines and in vitro diagnostics to the benefit of patients. We make

investments in life science companies aiming to create value by fostering innovation, guiding successful businesses and generating financial return to Roche.

Our commitment to investments is not just about funding - we provide our team's expertise and the promise of long term vision to drive our shared success together.

The Roche Venture Fund invests to develop commercially successful innovative life science companies.

www.roche.com/venturefund.htm



Syncona's purpose is to invest to extend and enhance human life. It does this by creating, building and

scaling companies to deliver transformational treatments to patients in areas of high unmet need, for the benefit of all our stakeholders. Syncona focuses on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Syncona's balance sheet underpins its strategy, enabling it to take a long-term view as the company looks to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders. www.synconaltd.com



UCB Ventures is an evergreen strategic corporate venture fund established in 2017 to create value from novel insights and technologies that can transform the lives of

patients suffering from severe diseases. We make long term investments in early-stage companies in the US and Europe. We seek breakthrough innovations in next-generation cell and gene therapy, regenerative medicine, cell and tissue homeostasis, and RNA modulation. We are known for our speed and agility, yet thoughtful and sophisticated approach. Above all, we are committed long term investors, working closely with entrepreneurs to bring out the best in our portfolio companies.

www.ucbventures.com



VIB is widely recognized as an established and world-leading knowledge center in life sciences and biotechnology with an excellent reputation in technology transfer. The unique combination of strategic basic research and a clear focus on innovation and business is one of the major contributors to its success. VIB is highly committed to being the driving force behind the growth of the dynamic life sciences clusters in Flanders.

VIB operates in close partnership with the five universities in Flanders – Ghent University, KU Leuven, University of Antwerp, Vrije Universiteit Brussel and Hasselt University. vib.be

SUPPORTING ORGANIZATIONS



B7% Europe

Breaking 7% is a networking group for women in Healthcare investment and BD deal-making roles. The representation of women in GP roles within the industry has ranged between 5% and 12% over the last decade. Originally established in the US, Breaking 7% aims to build stronger connections between women across the industry and promote professional growth. earlybirdhealth.notion.site/breaking-7-europe-2c90640d393b434bab37fa0723cea403



The BioIndustry Association (BIA) is the voice of the innovative life sciences and biotech industry, enabling and connecting the UK ecosystem so that businesses can start, grow and deliver world-changing innovation.

Established 33 years ago, BIA is the award-winning trade association with more than 500 members including: Start-ups, biotechnology and innovative life science companies; Pharmaceutical and technological companies; Universities, research centres, tech transfer offices, incubators and accelerators; A wide range of life science service providers: investors, lawyers, IP consultants, IR agencies.

BIA is the key thought leader for the sector – working across a wide range of related issues including policy, finance, science, regulatory, legal and talent on topics including engineering biology and techbio.

We promote an ecosystem that enables innovative life science companies to start and grow successfully and sustainably, and we do this through Influence, Connect, Save. www.bioindustry.org



BIOTECH AUSTRIA is the association of the Austrian biotechnology industry and has set itself the goal of supporting the development of an innovative branch of industry based on modern life sciences. biotechaustria.org



HollandBIO represents and connects the life sciences companies in the Netherlands. Together we work on our future ideal: a society in which biotechnology makes a maximum contribution to health, sustainability and economic growth.

To ensure that biotech innovations are quickly and widely available, HollandBIO tackles obstacles that stand in the way of the ambitions of the biotech leaders. We go for progress, even when we have to question the status quo.

www.hollandbio.nl/over-hollandbio



CONSILIUM

We are a global leader in strategic communications and investor relations, focused on the healthcare sector. Part of ICR, we are experts across all sub-sectors of healthcare and financial markets and our specialist teams in Europe and the US, enhance profile, reputation and perception with key audiences for a wide range of international healthcare companies. consilium-comms.com



Lingmed Ltd was founded in 2013 in Hong Kong. Currently we have offices in Shanghai, Beijing and Munich. Lingmed promotes intelligence databases and connects cross border innovations between east and west. www.lingmed.net



LYONBIPOLE
AUVERGNE-RHÔNE-ALPES
THE HEALTH INNOVATION NETWORK

As a French biocluster, Lyonbiopole Auvergne-Rhône-Alpes is the gateway to healthcare innovation in Auvergne-Rhône-Alpes, France. It aims to federate the actors of innovation, to connect and promote them internationally and to support the emergence and development of innovative technologies, products and services to address global healthcare challenges.

In 2024, Lyonbiopole Auvergne-Rhône-Alpes brings together a community of more than 250 members among which world-class leaders, innovative small and medium size companies, research centers and university hospitals. At the center of this ecosystem, Lyonbiopole supports its members' initiatives to imagine the future of medicine and to develop breakthrough healthTech innovation available for tomorrow's patients. lyonbiopole.com/en

24. BIO€QUITY
EUROPE

BIOEQUITYEUROPE.COM

ORGANIZED BY: BIOCENTURY EBD

MAY 12-14 KURSAAL ELKARGUNEA CENTER
SAN SEBASTIÁN, SPAIN
MAY 21-22 VIRTUAL 1x1 MEETINGS



Led by industry leaders, we provide strategic communications support to our clients across the UK, Europe and US. Our team has vast experience of

working in the healthcare and life sciences sectors and has advised on numerous cross border transactions, including on the London Stock Exchange, Euronext and NASDAQ.

We have long established partnerships with our network in Sweden, The Netherlands, Switzerland and the US.

www.optimumcomms.com

SIDLEY

Sidley is a global law firm with more than 150 years history and committed to providing excellent

client service, fostering a culture of cooperation and mutual respect. Sidley's pioneering Global Life Sciences practice comprises an experienced team of approximately 200 lawyers across numerous legal disciplines in our offices around the world. Advising on the full scope of regulatory, compliance and enforcement, litigation and transactional matters, Sidley team offers clients a holistic legal approach that will smooth the path to navigate industry changes, technological advances, market demands and policy hurdles.

www.sidley.com/en/global/services/life-sciences

swedenBIO

The Swedish Life Science Industry Organization

SwedenBIO is the national non-profit association for the life science industry in Sweden, with more than 300 members. Sweden has an innovative life science industry, strong academia and world leading infrastructure for research.

Our members are companies active within pharma, biotech, diagnostics and medtech and comprise the entire range from small start-ups, to SMEs and large enterprises. Many are engaged in research and development. Other members are experts in fields such as IP, law, finance, product development, life science communication and business development.

swedenbio.se/information-in-english



YVC collective is a network of emerging life sciences venture capital (VC) players. We create events and meet-ups for YVCs to

promote a closer connection between professionals in the life science VC industry in Europe. Our different events aim to drive career development and foster collaboration and knowledge exchange. yvc-collective.com

THE BIOCENTURY SHOW

Tune in to BioCentury's twice-monthly interview series with industry leaders who are advancing the future of medicine. Available for free via webcast or podcast.

Recent guests include:

- **Robert Nelsen**, Managing Director, Arch Venture Partners
- **Khoo Shih**, Ph.D., ClavystBio
- **Simeon George**, M.D., CEO & Managing Partner, SR One
- **Fiona Marshall**, Ph.D., President, Novartis Biomedical Research
- **Gil Bar-Nahum**, Ph.D., Managing Director, Jefferies International

To View Recent Episodes,
Visit: BioCenturyYouTube.com





REGISTER ONLINE — WWW.BIOEQUITYEUROPE.COM

VISA INFORMATION:

For visa requirements, please visit the [website of the responsible Spanish ministry](#).

Should you require an invitation letter for your visa application, please email EBDbilling@informa.com with the information below, and they will be happy to issue the letter for you.


Full Name as shown on passport

Passport Number

Date of Issue

Date of Expiry

Date of Birth



OFFICIAL TRAVEL GUIDE:

[Click here to download the official BioEquity Europe 2024 Travel Guide.](#)



REGISTRATION / PRICING SCHEDULE

- **All Access Pass: €2885 + 21% VAT**
book by April 2 and save €300
- **All Access Service Provider: €3450 + 21% VAT**
book by April 2 and save €250
- **Digital Access Pass: €2095**
- **Full Presenting Company Slots: €5250**
book by April 2 and save €500
- **Presenting Company Poster Spotlight Add On: €695**

GROUP DISCOUNT PRICING:

Discounts are available for groups of five (5) or more from any one company. For additional information and pricing, please email:

bioequityhelp@biocentury.com

BioEquity Europe 2024 will take place at the:

Kursaal Elkargunea Center

Zurriola Hiribidea, 1
20002 Donostia - San Sebastián

To book accommodations at a conference-affiliated hotel, please visit our Hotel & Travel page at: <https://conferences.biocentury.com/bioequity-europe-2024/hotel-and-travel>